This is a Phase 1 open-label study of the effect of itraconazole on the pharmacokinetics of CTP-543 in healthy subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
22
Itraconazole in solution dosage form
Clinical Pharmacology of Miami
Miami, Florida, United States
AUC0-t
Area Under the Plasma Concentration-Time Profile
Time frame: 48 hours
AUC0-inf
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time
Time frame: 48 hours
Cmax
Maximum observed concentration of drug in plasma
Time frame: 48 hours
Tmax
Time to reach maximum observed concentration of drug in plasma
Time frame: 48 hours
Number of Participants with Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention
Time frame: Up to 40 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.